Andis Graudins1,2,3, Robert Meek2,3, Jacqueline Parkinson4,3, Diana Egerton-Warburton5,3, Alastair Meyer6,3. 1. Monash Health Emergency Medicine Research Unit, Dandenong Hospital, Melbourne, Victoria, Australia. 2. Monash Emergency, Dandenong Hospital, Melbourne, Victoria, Australia. 3. School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia. 4. Pharmacy Department, Monash Medical Center, Melbourne, Victoria, Australia. 5. Monash Emergency, Monash Medical Center, Melbourne, Victoria, Australia. 6. Monash Emergency, Casey Hospital, Melbourne, Victoria, Australia.
Abstract
OBJECTIVE: Compare pain relief from non-opioid, codeine and oxycodone analgesic regimens in adults with moderate pain from limb injury. METHOD: Double-blind, randomised, controlled, non-inferiority trial. Three regimens of six tablets, each included 2 × 500 mg paracetamol and 2 × 200 mg ibuprofen with 2 × 100 mg thiamine (non-opioid), 2 × 30 mg codeine (codeine) or 2 × 5 mg oxycodone tablets (oxycodone). PRIMARY OUTCOME: difference in mean visual analogue scale (VAS) change between groups at 30 min, with a limit of inferiority of 13. Secondary outcomes included mean change in VAS rating from baseline to 30 min for each group, patient satisfaction, need for additional analgesia and adverse events. Pain ratings taken at 60 and 90 min for patients still in ED are described. RESULTS: Of 182 patients randomised, non-opioid, codeine and oxycodone numbers were 61, 62 and 59. Differences (95% CI) between groups at 30 min were as follows: non-opioid versus codeine -2.6 (-8.8 to 3.6); non-opioid versus oxycodone -2.7 (-9.3 to 3.9); codeine versus oxycodone 0.1 (-6.6 to 6.4). Mean VAS reductions for non-opioid, codeine and oxycodone were -13.5, -16.1 and -16.2 mm, respectively. Satisfaction with analgesia was reported by 77.6% (64.7-87.5), 81.0% (67.2-89.0) and 73.6% (59.7-84.7) and adverse events by 3.3% (0.4-11.3), 1.6% (0.4-8.7) and 16.9% (8.4-29.0), respectively. Mean VAS reductions at 60 and 90 min were as follows: -23.2 and -18.7 mm for non-opioid; -30.7 and -33.3 mm for codeine; and -26.1 and -31.7 mm for oxycodone. CONCLUSION: At 30 min, analgesic effects of non-opioid, codeine and oxycodone groups were non-inferior.
RCT Entities:
OBJECTIVE: Compare pain relief from non-opioid, codeine and oxycodone analgesic regimens in adults with moderate pain from limb injury. METHOD: Double-blind, randomised, controlled, non-inferiority trial. Three regimens of six tablets, each included 2 × 500 mg paracetamol and 2 × 200 mg ibuprofen with 2 × 100 mg thiamine (non-opioid), 2 × 30 mg codeine (codeine) or 2 × 5 mg oxycodone tablets (oxycodone). PRIMARY OUTCOME: difference in mean visual analogue scale (VAS) change between groups at 30 min, with a limit of inferiority of 13. Secondary outcomes included mean change in VAS rating from baseline to 30 min for each group, patient satisfaction, need for additional analgesia and adverse events. Pain ratings taken at 60 and 90 min for patients still in ED are described. RESULTS: Of 182 patients randomised, non-opioid, codeine and oxycodone numbers were 61, 62 and 59. Differences (95% CI) between groups at 30 min were as follows: non-opioid versus codeine -2.6 (-8.8 to 3.6); non-opioid versus oxycodone -2.7 (-9.3 to 3.9); codeine versus oxycodone 0.1 (-6.6 to 6.4). Mean VAS reductions for non-opioid, codeine and oxycodone were -13.5, -16.1 and -16.2 mm, respectively. Satisfaction with analgesia was reported by 77.6% (64.7-87.5), 81.0% (67.2-89.0) and 73.6% (59.7-84.7) and adverse events by 3.3% (0.4-11.3), 1.6% (0.4-8.7) and 16.9% (8.4-29.0), respectively. Mean VAS reductions at 60 and 90 min were as follows: -23.2 and -18.7 mm for non-opioid; -30.7 and -33.3 mm for codeine; and -26.1 and -31.7 mm for oxycodone. CONCLUSION: At 30 min, analgesic effects of non-opioid, codeine and oxycodone groups were non-inferior.
Authors: Juan Carlos C Montoy; Zlatan Coralic; Andrew A Herring; Eben J Clattenburg; Maria C Raven Journal: JAMA Intern Med Date: 2020-04-01 Impact factor: 21.873
Authors: Cecile A Feldman; Janine Fredericks-Younger; Shou-En Lu; Paul J Desjardins; Hans Malmstrom; Michael Miloro; Gary Warburton; Brent Ward; Vincent Ziccardi; Daniel Fine Journal: Trials Date: 2022-02-17 Impact factor: 2.279
Authors: Deepanjli Donthula; Christopher R Conner; Van Thi Thanh Truong; Charles Green; Chuantao Jiang; Michael W Wandling; Spogmai Komak; Todd F Huzar; Sasha D Adams; Daniel J Freet; David J Wainwright; Charles E Wade; Lillian S Kao; John A Harvin Journal: J Burn Care Res Date: 2021-11-24 Impact factor: 1.845
Authors: Phillip Aitken; Ioana Stanescu; Rebecca Playne; Jennifer Zhang; Christopher M A Frampton; Hartley C Atkinson Journal: J Pain Res Date: 2019-02-08 Impact factor: 3.133